Shockwave Medical CFO Dan Puckett to Retire in 2024

Shockwave Medical announced that chief financial officer (CFO) Dan Puckett plans to retire in Q1 2024. Puckett has been the company’s CFO since joining Shockwave in 2016.
 
The company said its board of directors began the process to identify a successor to Puckett. He plans to continue as CFO until his successor is named.
 
“I want to thank Dan for his years of dedication to Shockwave and his contributions to our growth and to our success as an organization,” Doug Godshall, CEO at Shockwave told the press. “Under his stewardship, which began before we even sold our first catheter, we executed multiple rounds of private funding and ultimately one of the most successful recent IPOs in our sector. Dan’s hard work helped establish the foundation that enabled Shockwave to build a unique and differentiated medical device enterprise in the cardiovascular space. For that, the team at Shockwave, our customers who use IVL and the many patients who have benefited from our technologies across the globe are grateful.”
 
Shockwave also revealed the appointment of Nick West, MA, MD, FRCP, FESC, FACC has joined the company as its new associate chief medical officer (CMO). Dr. West will report to current CMO Keith Dawkins, MD, with plans to succeed him as CMO in mid-2024.
 
Dr. West was previously CMO and divisional VP of Global Medical Affairs at Abbott Vascular for the past four years. Before Abbott, he was an attending cardiologist at the Royal Papworth Hospital NHS Foundation Trust in Cambridge, U.K.
 
“Dr. West brings to Shockwave a wealth of expertise in the interventional cardiology space,” said Dr. Dawkins. “Having known Nick for many years, I am confident that his expertise will be highly influential in further developing Intravascular Lithotripsy (IVL) as the standard of care for calcium modification, and will also be a valued asset in the evaluation and development of novel transformational technologies to augment our portfolio in the years to come.”
 
Shocwave Medical’s first-of-its-kind Intravascular Lithotripsy (IVL) tech has changed the way calcium is managed during treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque.